Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus RENOVUE 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus RENOVUE 65.
HYPAQUE-CYSTO vs RENOVUE-65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Iothalamate meglumine is an ionic, high-osmolality iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It acts by increasing the radiopacity of blood vessels and organs during imaging.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
Intravenous injection, 10 mL (6.48 g iobitridol) as a single dose. Repeat dosing: up to 3 additional doses within 30 minutes, maximum 40 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal elimination half-life: 2.0 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <10 mL/min).
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Renal: 100% as unchanged drug; no biliary or fecal elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent